Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 3 · below the Ichimoku cloud · RSI 34 · MACD below its signal
None of the 29 investors followed here reported a position in SPRC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SPRC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 31, 2026 | Shrem ItschakDirector | Sale at price 10.00 per share. | 462 | $4.62K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -43.5 | -27.8 | -26.7 | 139.6 | 11.9 | -43.7 | 29.0 | -6.9 | -28.8 | -16.5 | −67.8% | ||
| 2025 | 25.0 | -17.1 | -22.3 | -5.5 | 14.6 | -1.0 | -12.4 | -57.0 | 145.5 | -46.2 | -32.3 | -38.2 | −82.0% |
| 2024 | -26.6 | 6.7 | -53.7 | -20.9 | -33.6 | -14.0 | -44.7 | -18.6 | -32.5 | 2.1 | -13.7 | 68.2 | −92.6% |
| 2023 | 19.0 | -15.6 | -40.8 | 55.3 | -4.1 | -18.1 | -14.6 | -65.9 | -15.9 | 60.6 | 39.0 | -37.5 | −75.2% |
| 2022 | -11.7 | -16.4 | -16.7 | -26.4 | 7.2 | -29.5 | -25.8 | -45.6 | -2.4 | 14.9 | 10.0 | -28.7 | −87.9% |
| 2021 | -3.6 | 16.1 | 11.6 | -11.0 | +11.3% |
No analyst coverage for this instrument.
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.